ACHILLION PHARMACEUTICALS IN's ticker is ACHN and the CUSIP is 00448Q201. A total of 152 filers reported holding ACHILLION PHARMACEUTICALS IN in Q2 2016. The put-call ratio across all filers is 0.32 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $78,979,000 | +78.9% | 13,097,546 | +6.8% | 0.00% | +50.0% |
| Q3 2019 | $44,157,000 | +34.4% | 12,265,849 | +0.1% | 0.00% | +100.0% |
| Q2 2019 | $32,851,000 | -7.0% | 12,257,553 | +2.7% | 0.00% | 0.0% |
| Q1 2019 | $35,323,000 | +157.8% | 11,933,406 | +38.5% | 0.00% | 0.0% |
| Q4 2018 | $13,701,000 | -68.2% | 8,617,525 | -26.4% | 0.00% | -50.0% |
| Q3 2018 | $43,106,000 | +37.1% | 11,713,540 | +5.4% | 0.00% | +100.0% |
| Q2 2018 | $31,448,000 | -21.9% | 11,112,054 | +2.3% | 0.00% | -50.0% |
| Q1 2018 | $40,283,000 | +29.4% | 10,857,813 | +0.5% | 0.00% | +100.0% |
| Q4 2017 | $31,130,000 | -26.4% | 10,808,995 | +14.8% | 0.00% | -50.0% |
| Q3 2017 | $42,286,000 | -3.8% | 9,417,843 | -1.6% | 0.00% | 0.0% |
| Q2 2017 | $43,946,000 | +8.9% | 9,574,335 | -0.1% | 0.00% | 0.0% |
| Q1 2017 | $40,357,000 | +9.3% | 9,585,823 | +7.2% | 0.00% | 0.0% |
| Q4 2016 | $36,920,000 | -47.4% | 8,939,408 | +3.2% | 0.00% | -50.0% |
| Q3 2016 | $70,186,000 | +6.4% | 8,664,957 | +2.5% | 0.00% | 0.0% |
| Q2 2016 | $65,947,000 | +6.8% | 8,454,713 | +5.7% | 0.00% | 0.0% |
| Q1 2016 | $61,756,000 | -25.5% | 7,999,462 | +4.1% | 0.00% | -33.3% |
| Q4 2015 | $82,896,000 | -82.7% | 7,682,621 | -68.1% | 0.01% | -66.7% |
| Q3 2015 | $477,964,000 | +683.1% | 24,097,365 | +249.8% | 0.02% | +350.0% |
| Q2 2015 | $61,037,000 | -4.3% | 6,889,017 | +6.5% | 0.00% | 0.0% |
| Q1 2015 | $63,799,000 | -5.1% | 6,470,429 | +17.9% | 0.00% | -20.0% |
| Q4 2014 | $67,204,000 | +34.7% | 5,486,021 | +9.8% | 0.01% | +25.0% |
| Q3 2014 | $49,879,000 | +34.7% | 4,997,815 | +2.2% | 0.00% | +33.3% |
| Q2 2014 | $37,017,000 | +119.8% | 4,889,994 | -4.5% | 0.00% | +200.0% |
| Q1 2014 | $16,842,000 | +8.2% | 5,118,926 | +9.1% | 0.00% | 0.0% |
| Q4 2013 | $15,572,000 | +19.2% | 4,690,543 | +8.4% | 0.00% | 0.0% |
| Q3 2013 | $13,068,000 | -61.8% | 4,327,155 | +3.6% | 0.00% | -75.0% |
| Q2 2013 | $34,182,000 | – | 4,178,753 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 13,633,220 | $56,305,000 | 7.98% |
| BVF INC/IL | 2,423,300 | $10,008,000 | 2.01% |
| EMORY UNIVERSITY | 454,102 | $1,875,000 | 1.85% |
| DAFNA Capital Management LLC | 196,500 | $812,000 | 0.71% |
| Orbimed Advisors | 13,107,200 | $54,133,000 | 0.69% |
| RTW INVESTMENTS, LP | 286,285 | $1,182,000 | 0.44% |
| Marcus Capital, LLC | 100,000 | $413,000 | 0.44% |
| Rock Springs Capital Management LP | 1,375,000 | $5,679,000 | 0.38% |
| Spark Investment Management LLC | 978,600 | $4,041,000 | 0.33% |
| Bellevue Group AG | 240,000 | $991,000 | 0.20% |